FDA-Approved Drug Effectively Treats Rare Chronic Immune Disorders | NIH: National Institute of Allergy and Infectious Diseases

FDA-Approved Drug Effectively Treats Rare Chronic Immune Disorders | NIH: National Institute of Allergy and Infectious Diseases

Wednesday, April 3, 2019 FDA-Approved Drug Effectively Treats Rare Chronic Immune Disorders   A drug approved to treat a severe form of asthma dramatically improved the health of people with rare chronic immune disorders called hypereosinophilic syndromes in whom other treatments were ineffective or intolerable. This finding comes from a small clinical trial led by NIAID scientists and conducted through a partnership with the global biopharmaceutical company AstraZeneca. The results were published online today in The New England Journal of Medicine.